M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Effect of disease burden on health-related quality of life in patients with malignant gliomas.
TL;DR: Most of the symptoms were likely due to recurrence, but previous radiation therapy and on-going corticosteroid treatment may have also been casual factors for fatigue, whereas uncertainty about the future and pain were probably nonspecific for brain cancer.
Journal ArticleDOI
Management of chiasmal and hypothalamic gliomas of infancy and childhood with chemotherapy.
Joseph A. Petronio,Michael S. B. Edwards,Michael D. Prados,Sarah Freyberger,Jane Rabbitt,Pamela Silver,Victor A. Levin +6 more
TL;DR: Preliminary results suggest that nitrosourea-based cytotoxic regimens are useful for the initial treatment of children with chiasmal/hypothalamic gliomas, and allow potentially harmful radiation therapy to be deferred until progression of disease.
Journal ArticleDOI
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
Courtney A. Crane,Seunggu J. Han,Brian J. Ahn,Jessica Oehlke,Valerie Kivett,Anne Fedoroff,Nicholas Butowski,Susan M. Chang,Jennifer Clarke,Mitchel S. Berger,Michael W. McDermott,Michael D. Prados,Andrew T. Parsa +12 more
TL;DR: These data provide the first evidence in humans of individual patient-specific immune responses against autologous tumor derived peptides bound to HSP-96, which is used to safely immunize patients with recurrent GBM.
Journal ArticleDOI
Radiation response and survival time in patients with glioblastoma multiforme
Fred G. Barker,Michael D. Prados,Susan M. Chang,Philip H. Gutin,Kathleen R. Lamborn,David A. Larson,Mary Malec,Michael W. McDermott,Penny K. Sneed,William M. Wara,Charles B. Wilson +10 more
TL;DR: The authors studied a cohort of 301 patients who were initially treated according to uniform clinical protocols and found that neuroimaging obtained within 3 days after surgery served as a better baseline for assessment of radiation response than images obtained later.
Journal ArticleDOI
18-fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma
Fred G. Barker,Fred G. Barker,Susan M. Chang,Peter E. Valk,Thomas R. Pounds,Michael D. Prados +5 more
TL;DR: After intensive initial radiation therapy for malignant glioma, magnetic resonance imaging (MRI) and computerized tomography (CT) cannot distinguish tumor progression from radiation injury.